GlassScriptPhysician profile
Resty T Tibayan
NPI 1508029208
$10,064.50
in general payments reported to CMS, 2019-2025
50 companies · $3,420 in 2025
The $3,420 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $435 · 2021: $244 · 2022: $701 · 2023: $1,404 · 2024: $3,280 · 2025: $3,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,788 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,788.34 |
| Education | $316.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,876.23 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $1,202.74 | 2020-2025 | |
| Exelixis INC. | $528.20 | 2021-2025 | Cabometyx |
| Gilead Sciences, INC. | $452.19 | 2019-2025 | Trodelvy |
| Sobi, INC | $406.24 | 2024-2025 | |
| Pfizer INC. | $374.23 | 2022-2025 | |
| Beigene USA, INC. | $370.12 | 2020-2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $352.67 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Tempus Ai, INC | $341.58 | 2024-2025 | Xt Cdx |
| Celgene Corporation | $322.47 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $285.16 | 2019-2025 | Opdualag, Opdivo, Eliquis |
| Abbvie INC. | $260.95 | 2022-2025 | Venclexta |
| Incyte Corporation | $206.69 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Novocure INC. | $196.35 | 2019-2025 | Optune Lua (Novottf-200t) |
| Pharmacosmos Therapeutics INC. | $171.34 | 2023-2025 | Monoferric |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $168.66 | 2022-2025 | Libtayo |
| Emd Serono, INC. | $168.44 | 2023-2025 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $167.12 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Lilly USA, LLC | $166.22 | 2021 | |
| Medtronic, INC. | $159.72 | 2024 | Vanta Adaptivestim |
| Janssen Biotech, INC. | $152.46 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Genentech USA, INC. | $148.36 | 2023-2025 | Phesgo, Kadcyla, Perjeta |
| Amgen INC. | $136.95 | 2022-2023 | Vectibix, Lumakras, Xgeva |
| Alexion Pharmaceuticals, INC. | $134.94 | 2024-2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $131.78 | 2023-2024 | Xpovio |
| Genzyme Corporation | $121.61 | 2022-2024 | |
| Eisai INC. | $115.44 | 2024 | |
| Astellas Pharma US INC | $103.10 | 2023-2025 | Xospata, Xtandi, Vyloy |
| Glaxosmithkline, LLC. | $100.69 | 2022-2025 | Ojjaara |
| Seagen INC. | $92.99 | 2025 | |
| Mirati Therapeutics, INC. | $90.85 | 2023-2024 | Krazati |
| Beone Medicines USA, INC. | $84.62 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $80.38 | 2022-2023 | Imbruvica |
| Genmab U.S., INC. | $61.59 | 2025 | Tivdak, Epkinly |
| Azurity Pharmaceuticals, INC. | $44.28 | 2025 | Danziten |
| Takeda Pharmaceuticals U.S.A., INC. | $30.06 | 2019-2024 | Alunbrig |
| Alnylam Pharmaceuticals INC. | $27.98 | 2025 | Amvuttra |
| Springworks Therapeutics, INC. | $25.53 | 2024 | Ogsiveo |
| Puma Biotechnology, INC. | $24.82 | 2025 | |
| Legend Biotech USA INC. | $24.44 | 2025 | Carvykti |
| Adaptive Biotechnologies Corporation | $21.45 | 2025 | Clonoseq |
| Bayer Healthcare Pharmaceuticals INC. | $21.00 | 2025 | |
| Coherus Oncology, INC. | $20.63 | 2024 | |
| Sirtex Medical INC | $20.17 | 2023 | Sir-Spheres Microspheres |
| Viiv Healthcare Company | $18.98 | 2025 | Apretude |
| Stemline Therapeutics INC. | $18.52 | 2023 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $17.92 | 2025 | Onivyde |
| Foundation Medicine, INC. | $12.81 | 2022 | |
| Array Biopharma INC | $2.83 | 2025 | Mektovi, Braftovi, Lorbrena |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Resty Tibayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.